CoronaVac

CoronaVac
Vaccine description
An empty vial of the CoronaVac vaccine
Target	SARS-CoV-2
Vaccine type	Inactivated
Clinical data
Trade names	CoronaVac
Other names	PiCoVacc
Routes of administration	Intramuscular
ATC code	J07BN03 (WHO)
Legal status
Legal status	BR: Emergency use Full list of CoronaVac authorizations
Identifiers
CAS Number	2480309-93-9
DrugBank	DB15806
UNII	M1QXB372B8

COVID-19 pandemic
Part of a series on the

COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Long COVID Neurological and psychological symptoms Post-exertional malaise Society African diaspora Indian migrant workers Animals Alzheimer's disease patients Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBTQ community Long-term care Media coverage Mental health Migration Military Notable deaths Other health issues Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Politics Diplomacy Infected leaders Ireland Malaysia New Zealand Russia UK US
COVID-19 portal

CoronaVac, also known as the Sinovac COVID-19 vaccine, was a whole inactivated virus SARS-CoV-2 vaccine developed by Sinovac and extensively deployed globally to control the COVID-19 pandemic. Its use was highest in low- and middle-income countries. In January 2024, Sinovac confirmed that production of CoronaVac had been discontinued.

Clinical trials have demonstrated that a standard two-dose regimen provides moderate efficacy against symptomatic COVID-19, ranging from about 50% to 83% depending on population and circulating viral variants, with more robust protection observed against severe disease, hospitalization, and death. Although most adverse reactions are mild and serious vaccine-related events are rare, the vaccine’s immune protection against symptomatic infection wanes over time, especially in the context of emerging variants such as Omicron, leading to recommendations for booster doses to sustain immunity and reduce severe outcomes. Overall, CoronaVac’s safety and efficacy profile in preventing severe COVID-19 have contributed to its use in vaccination programs, particularly in regions with limited access to mRNA vaccines.

On 1 June 2021, the World Health Organization (WHO) validated CoronaVac for emergency use. Sinovac subsequently signed agreements to supply 380 million doses to COVAX.

By July 2021, CoronaVac was the most widely used COVID-19 vaccine globally, with about 943 million doses delivered. As of 14 October 2021, it remained the vaccine with the highest number of doses administered worldwide.